Revolution Medicines Launches Phase 3 Trial for RAS G12D Pancreatic Cancer Combination Therapy
Event summary
- Revolution Medicines has initiated patient treatment in the Phase 3 RASolute 309 trial evaluating RASONQUE (daraxonrasib) plus zoldonrasib as a first-line treatment for metastatic RAS G12D pancreatic cancer.
- The trial is a global, randomized, open-label study comparing the combination therapy to the standard of care, gemcitabine and nab-paclitaxel (GnP).
- Primary endpoints include progression-free survival (PFS) and overall survival, with key secondary endpoints focusing on safety, tolerability, and patient-reported outcomes.
- RAS G12D is the most common RAS variant in pancreatic cancer, occurring in 40% of patients.
The big picture
Revolution Medicines is advancing a novel approach to targeting RAS-driven cancers, a historically challenging area due to the lack of effective therapies. The Phase 3 trial represents a critical step in validating the company's RAS(ON) tri-complex inhibitor platform, which could potentially transform the treatment landscape for pancreatic cancer and other RAS-addicted malignancies. The success of this trial could position Revolution Medicines as a leader in precision oncology, addressing a significant unmet need in cancer care.
What we're watching
- Clinical Efficacy
- Whether the combination of RASONQUE and zoldonrasib will demonstrate superior efficacy over the current standard of care in first-line treatment of metastatic RAS G12D pancreatic cancer.
- Regulatory Pathway
- The pace at which Revolution Medicines can advance through the Phase 3 trial and potentially secure regulatory approval for this combination therapy.
- Market Adoption
- How the oncology community and regulatory bodies will respond to the initial data from this Phase 3 trial, which could influence future treatment paradigms for RAS-driven cancers.
